Abstract
Clinical data of patients suffering from COVID-19 have indicated that statin therapy, used to treat hypercholesterolemia, is associated with a better clinical outcome. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that fluvastatin inhibited coronavirus infection, while other tested statins did not. Fluvastatin inhibited high and low pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Proteomic analyses of infected versus uninfected lung epithelial cells treated with fluvastatin, simvastatin, or rosuvastatin revealed that all tested statins modulated the cholesterol synthesis pathways without compromising the innate antiviral immune response. Strikingly, fluvastatin treatment uniquely affected the proteome of SARS-CoV-2 infected cells, specifically downregulating proteins that modulate protein translation and viral replication. These results suggest that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin may have a moderate beneficial effect on SARS-CoV-2 infection by modulating protein translation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
G.G. was supported by the Knut and Alice Wallenberg Foundation, the Federal Ministry of Education and Research together with the Ministry of Science and Culture of Lower Saxony through the Professorinnen Programm III, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 158989968 - SFB 900 project C7 and the DFG project GE 2145/3-2 to G.G, the German Academic Exchange Service (DAAD) to J.K. and the Federal Ministry of Education and Research (project COVID-Protect, Projektnummer 01KI20143C) to F.J.Z.B. The work was further funded by the Infection Biology International PhD Program of Hannover Biomedical Research School to R.M., the German Centre for Infection Research (DZIF) to A.P.G. and T.P., the Helmholtz Alberta Initiative for Infectious Disease Research (HAI-IDR), the Shandong University Helmholtz International Laboratory to T.P, and the SciLifeLab/KAW national COVID-19 research program project grant 2020 and the Heart- and Lung foundation project grant for COVID-19 (project number 20200385) to A.K.O. and by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement No 871029.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have obtained ethical permission from the regionala etikprovningsnamnden in Umea to isolate human bronchial epithelial cells (HBEC) from lung resection surgery (Dnr. 2014/395-31).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Whole cell proteomics data included
Data Availability
No additional data reported or deposited
